2020

26/11/2020

Results of Annual General Meeting 2020

26/11/2020

AGM Investor Presentation 2020

12/11/2020

Middle East is next market for PromarkerD immunoassay test

05/11/2020

PromarkerD clinical assay performance results published

03/11/2020

Change in substantial holding – Lipscombe – PIQ

03/11/2020

Change in substantial holding – Dunlop – PIQ

03/11/2020

Proteomics receives 1.1 million in R&D tax incentive

02/11/2020

Appendix 2A – Completion of Placement

28/10/2020

Appendix 4C – September 2020 Quarterly Update

23/10/2020

Proposed issue of Securities – PIQ – Ordinary Fully Paid

23/10/2020

Proposed issue of Securities – PIQ – Unquoted options

23/10/2020

Proteomics International raises $6m in successful Placement

16/10/2020

First distribution agreement for PromarkerD immunoassay

12/10/2020

PromarkerD international validation study results published

09/10/2020

Partnership with QIMR Berghofer targets oesophageal cancer

29/09/2020

Change of Director’s Interest Notice

31/08/2020

Annual Report to shareholders

31/08/2020

Preliminary Final Report

31/08/2020

Corporate Governance Statement and Appendix 4G

26/08/2020

Investor Presentation – August 2020

18/08/2020

Proposed issue of Securities – PIQ

18/08/2020

Issue of Corporate Advisory Options and Secondary Trading No

29/07/2020

Appendix 4C – June 2020 Quarterly Update

27/07/2020

PromarkerD Intellectual Property portfolio expands

30/06/2020

Updated Trading Policy

29/06/2020

Appendix 3Y – Directors on-market purchase of shares

15/06/2020

Appendix 2A – Exercise of Employee Options

14/06/2020

Big pharma clinical study validates PromarkerD kidney test

09/06/2020

PIQ Investor Presentation – 9th June 2020

25/05/2020

Proteomics International receives COVID-19 research grants

28/04/2020

Appendix 4C – March 2020 Quarterly Update

16/04/2020

CE Mark for PromarkerD Immunoassay Kit

07/04/2020

Diagnostics R&D expanded: the Promarker™ Pipeline

31/03/2020

Proteomics International expands study with US big pharma

27/03/2020

Proposed Issue of Securities

27/03/2020

Issue of Corporate Advisory Options

27/03/2020

Outcome of Extraordinary General Meeting

23/03/2020

Proteomics International to patent biomarkers for diagnosis of endometriosis

27/02/2020

PIQ Half Year Report Appendix 4D

10/02/2020

PromarkerD presented at Australasian Proteomics conference

30/01/2020

Appendix 4C – December 2019 Quarterly Update

14/01/2020

CE Mark for PromarkerD Hub predictive software for DKD

Subscribe
  • This field is for validation purposes and should be left unchanged.